Research Topics
Species | Gal BitanSummaryAffiliation: University of California Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
Paradigm shifts in Alzheimer's disease and other neurodegenerative disorders: the emerging role of oligomeric assembliesMarina D Kirkitadze
Department of Neurology, Harvard Medical School, Boston, Massachusetts, USA
J Neurosci Res 69:567-77. 2002..The archetypal features of the assembly-dependent neuropathogenetic effects of Abeta may thus be of relevance not only to AD but to these other disorders as well...- Amyloid beta -protein (Abeta) assembly: Abeta 40 and Abeta 42 oligomerize through distinct pathwaysGal Bitan
Center for Neurologic Diseases, Brigham and Women's Hospital, Boston, MA 02115, USA
Proc Natl Acad Sci U S A 100:330-5. 2003..The strong etiologic association of Abeta42 with AD may thus be a result of assemblies formed at the earliest stages of peptide oligomerization... - Elucidation of primary structure elements controlling early amyloid beta-protein oligomerizationGal Bitan
Center for Neurologic Diseases, Brigham and Women's Hospital, and Department of Neurology, Harvard Medical School, Boston, Massachusetts 02115, USA
J Biol Chem 278:34882-9. 2003..These results reveal how specific regions and residues control A beta oligomerization and show that these controlling elements differ between A beta 40 and A beta 42... - Increased T cell reactivity to amyloid beta protein in older humans and patients with Alzheimer diseaseAlon Monsonego
Center for Neurologic Diseases, Harvard Medical School and Brigham and Women's Hospital, Boston, Massachusetts 02115, USA
J Clin Invest 112:415-22. 2003.... - A molecular switch in amyloid assembly: Met35 and amyloid beta-protein oligomerizationGal Bitan
Center for Neurologic Diseases, Brigham and Women's Hospital, Boston, MA 02115, USA
J Am Chem Soc 125:15359-65. 2003..Preventing assembly of toxic Abeta42 paranuclei through selective oxidation of Met(35) thus represents a potential therapeutic approach for AD... - Neurotoxic protein oligomers--what you see is not always what you getGal Bitan
Department of Neurology, David Geffen School of Medicine at UCLA, 90095 7334, USA
Amyloid 12:88-95. 2005.... - Biophysical characterization of Abeta42 C-terminal fragments: inhibitors of Abeta42 neurotoxicityHuiyuan Li
Department of Neurology, David Geffen School of Medicine, University of California, Los Angeles, 635 Charles E Young Drive, Los Angeles, California 90095, USA
Biochemistry 49:1259-67. 2010..The data enhance our understanding of the physical characteristics that affect CTF activity and advance our ability to design, synthesize, and test future generations of inhibitors... - Mechanistic investigation of the inhibition of Abeta42 assembly and neurotoxicity by Abeta42 C-terminal fragmentsHuiyuan Li
Department of Neurology, David Geffen School of Medicine, University of California Los Angeles, 635 Charles E Young Drive S, Los Angeles, CA 90095, USA
Biochemistry 49:6358-64. 2010.... - Despite its role in assembly, methionine 35 is not necessary for amyloid beta-protein toxicityPanchanan Maiti
Department of Neurology, David Geffen School of Medicine, University of California, Los Angeles, California 90095, USA
J Neurochem 113:1252-62. 2010.... - RNA aptamers generated against oligomeric Abeta40 recognize common amyloid aptatopes with low specificity but high sensitivityFarid Rahimi
Department of Neurology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, USA
PLoS ONE 4:e7694. 2009..Nevertheless, the high sensitivity, whereby aptamers detect beta-sheet formation, suggests that they can serve as superior amyloid recognition tools... - A two-step strategy for structure-activity relationship studies of N-methylated a?42 C-terminal fragments as a?42 toxicity inhibitorsHuiyuan Li
Department of Neurology, David Geffen School of Medicine, University of California Los Angeles UCLA, 635 Charles E Young Drive S, Los Angeles, CA 90095, USA
ChemMedChem 7:515-22. 2012.... - Amino acid position-specific contributions to amyloid beta-protein oligomerizationSamir K Maji
Department of Neurology, UCLA, Los Angeles, California 90095, USA
J Biol Chem 284:23580-91. 2009.... - Elucidating amyloid beta-protein folding and assembly: A multidisciplinary approachDavid B Teplow
Department of Neurology, David Geffen School of Medicine, Brain Research Institute, and Molecular Biology Institute, University of California, Los Angeles, California 90095, USA
Acc Chem Res 39:635-45. 2006..An integrated multidisciplinary program is required. We discuss here the synergistic application of in hydro, in vacuo, and in silico methods to the study of the amyloid beta-protein, the key pathogenetic agent in Alzheimer's disease... - Early diagnostics and therapeutics for Alzheimer's disease--how early can we get there?Bernhard H Monien
Department of Neurology, David Geffen School of Medicine, University of California at Los Angeles, Neuroscience Research Building 1, Room 455, 635 Charles E Young Drive South Los Angeles, CA 90095 7334, USA
Expert Rev Neurother 6:1293-306. 2006..Nevertheless, new insights into the earliest events that lead to development of AD increase hope that reliable diagnostics and efficacious therapies may emerge... - Preparation of Stable Amyloid ?-Protein Oligomers of Defined Assembly OrderClark Rosensweig
Department of Neurology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
Methods Mol Biol 849:23-31. 2012..This method has been used successfully to provide material for formal structure-activity studies of A? oligomers... - Lysine-specific molecular tweezers are broad-spectrum inhibitors of assembly and toxicity of amyloid proteinsSharmistha Sinha
Department of Neurology, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, California 90095, USA
J Am Chem Soc 133:16958-69. 2011..The data suggest that molecular tweezers are unique, process-specific inhibitors of aberrant protein aggregation and toxicity, which hold promise for developing disease-modifying therapy for amyloidoses... - Application of Photochemical Cross-linking to the Study of Oligomerization of Amyloidogenic ProteinsDahabada H J Lopes
Department of Neurology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
Methods Mol Biol 849:11-21. 2012..The method has provided insights into the factors controlling early oligomerization, which could not be obtained by other means. We discuss sample preparation, experimental details, optimization of parameters, and troubleshooting... - Structural study of metastable amyloidogenic protein oligomers by photo-induced cross-linking of unmodified proteinsGal Bitan
UCLA, Department of Neurology, David Geffen School of Medicine, Los Angeles, CA, USA
Methods Enzymol 413:217-36. 2006.... - A Novel "Molecular Tweezer" Inhibitor of ?-Synuclein Neurotoxicity in Vitro and in VivoShubhangi Prabhudesai
Department of Neurology, UCLA David Geffen School of Medicine, Los Angeles, CA, 90095, USA
Neurotherapeutics 9:464-76. 2012..Treatment with CLR01 almost completely mitigated the proteasome inhibition. The data suggest that CLR01 is a promising therapeutic agent for the treatment of Parkinson's disease and other synucleinopathies... - Surprising toxicity and assembly behaviour of amyloid ?-protein oxidized to sulfonePanchanan Maiti
Department of Neurology, University of California at Los Angeles, 90025, USA
Biochem J 433:323-32. 2011..These surprising data decouple the toxicity of oxidized A? from its initial oligomerization, and suggest that our current understanding of the effect of methionine oxidation in A? is limited... - C-terminal peptides coassemble into Abeta42 oligomers and protect neurons against Abeta42-induced neurotoxicityErica A Fradinger
Department of Neurology, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA
Proc Natl Acad Sci U S A 105:14175-80. 2008..Thus, Abeta(31-42) and Abeta(39-42) are leads for obtaining mechanism-based drugs for treatment of AD using a systematic structure-activity approach... - En route to early diagnosis of Alzheimer's disease--are we there yet?Erica A Fradinger
Department of Neurology, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA
Trends Biotechnol 23:531-3. 2005..This assay appears to be more specific for AD than previous ELISA-based work and, if specificity of the assay for Abeta oligomers can be established, the method developed might provide a sensitive, reliable diagnostic tool for AD... - Rapid photochemical cross-linking--a new tool for studies of metastable, amyloidogenic protein assembliesGal Bitan
Center for Neurologic Diseases, Brigham and Women s Hospital and Department of Neurology, Harvard Medical School, Boston, MA 02115, USA
Acc Chem Res 37:357-64. 2004..The method provides essential insights into the factors that control the assembly of pathogenic protein oligomers, facilitating efforts toward the development of therapeutic agents... - Amyloid beta-protein monomer structure: a computational and experimental studyAndrij Baumketner
Department of Chemistry and Biochemistry, University of California, Santa Barbara, CA 93106-9501, USA
Protein Sci 15:420-8. 2006..Implications of the calculations on the early stages of aggregation of Abeta42 are discussed... - Dendrimeric Abeta1-15 is an effective immunogen in wildtype and APP-tg miceTimothy J Seabrook
Center for Neurologic Diseases, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, United States
Neurobiol Aging 28:813-23. 2007..Anti-Abeta antibodies bound monomeric, oligomeric, and fibrillar Abeta. Our data suggest that dAbeta1-15 may be an effective and potentially safer immunogen for Alzheimer's disease (AD) vaccination... - Determination of Peptide oligomerization state using rapid photochemical crosslinkingSabrina S Vollers
Center for Neurologic Diseases, Brigham and Women's Hospital and Department of Neurology, Harvard Medical School, Boston, MA, USA
Methods Mol Biol 299:11-8. 2005..PICUP provides a snapshot of the native oligomerization state of proteins and can be used for assembly state analysis of a wide variety of peptides and proteins... - Preparation of aggregate-free, low molecular weight amyloid-beta for assembly and toxicity assaysGal Bitan
Center for Neurologic Diseases, Brigham and Women's Hospital and Department of Neurology, Harvard Medical School, Boston, MA, USA
Methods Mol Biol 299:3-9. 2005..In this chapter, we describe the preparation of LMW Abeta using size exclusion chromatography and filtration. The advantages and disadvantages of each method are discussed... - Amyloid beta-protein: monomer structure and early aggregation states of Abeta42 and its Pro19 alloformSummer L Bernstein
Department of Chemistry and Biochemistry, University of California, Santa Barbara, California 93106-9501, USA
J Am Chem Soc 127:2075-84. 2005..These results are consistent with recently published photochemical cross-linking data and lend support to recent aggregation mechanisms proposed by Bitan, Teplow, and co-workers [J. Biol. Chem. 2003, 278, 34882-34889]...
Research Grants
- Novel Specific Ligands for ABeta OligomersGal Bitan; Fiscal Year: 2007....